PhaseBio Pharmaceuticals Inc.
13 clinical trials · Sponsor
◉ Watch PhaseBio Pharmaceuticals Inc.
| Record | Firm | Date |
|---|---|---|
| Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). (NCT04433546) | PhaseBio Pharmaceuticals Inc. | 2020-07-15 |
| Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (NCT03795428) | PhaseBio Pharmaceuticals Inc. | 2019-04-10 |
| Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH (NCT03556020) | PhaseBio Pharmaceuticals Inc. | 2018-07-15 |
| A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH (NCT03315507) | PhaseBio Pharmaceuticals Inc. | 2017-10-20 |
Track PhaseBio Pharmaceuticals Inc. automatically
Every clearance here is in the API, with alerts when new ones post.